BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,021.63
0.57%
US Tech 100
20,355.20
0.45%
Dow Jones
44,860.31
0.28%
Brent Oil
72.355
-0.13%
Bitcoin
92,601.73
0.68%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Gilead Sciences Inc (GILD) Quote

Gilead Sciences Inc

Gilead Sciences Inc (GILD)

DMG Mori AG
DMG Mori AG
DMG Mori AG
DMG Mori AG
Guild Esports Plc
91.35
0.86
(0.95%)
Closed November 26 4:00PM
Delayed by 15 minutes
91.76
0.41
(0.45%)
After Hours: 7:56PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
91.76
Bid
91.04
Ask
91.70
Volume
4,374,629
89.63 Day's Range 91.68
62.07 52 Week Range 98.90
Market Cap
114.357B
Previous Close
90.49
Open
90.40
Last Trade
100
@
91.76
(formt)
Last Trade Time
Financial Volume
$ 396,706,249
VWAP
90.6834
Average Volume (3m)
6,843,962
Shares Outstanding
1,246,265,857
Dividend Yield
3.36%
PE Ratio
20.10
Earnings Per Share (EPS)
4.55
Revenue
27.12B
Net Profit
5.67B

About Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.gilead.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was $90.49. Over the last year, Gilead Sciences shares have traded in a share price range of $ 62.07 to $ 98.90.

Gilead Sciences currently has 1,246,265,857 shares outstanding. The market capitalization of Gilead Sciences is $112.77 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 20.10.

Ask ADVFN Intelligence (AI)

Gilead Sciences (GILD) Options Flow Summary

GILD Options Flow

Overall Flow

Bullish

Net Premium

157k

Calls / Puts

300.00%

Buys / Sells

0.00%

OTM / ITM

33.33%

Sweeps Ratio

0.00%

GILD Latest News

More News

Form 144 - Report of proposed sale of securities

3 hours ago
Edgar (US Regulatory)

Form 8-K - Current report

November 20 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

November 15 2024
Edgar (US Regulatory)

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

– New Findings Demonstrate 81% of Participants Achieve Durable Biochemical Response by Month 30 with Livdelzi – – Nearly Half of Participants with Primary Biliary Cholangitis (PBC) Achieve...

November 15 2024
Business Wire

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior...

November 13 2024
Business Wire

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

November 13 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

November 13 2024
Edgar (US Regulatory)

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

– Newly Presented Results, to be Published in The New England Journal of Medicine, Include Adherence and Pharmacokinetics Data; Data Underscore High Efficacy and Safety Profile of Lenacapavir...

November 13 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 12 2024
Edgar (US Regulatory)

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

– Four-Year Outcomes from the BICSTaR Study Further Demonstrate the Long-Term Efficacy and Safety Profile of Biktarvy®, Providing Insights for HIV Clinical Care – – New Data on HIV Treatment...

November 12 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
14.134.7129978317987.6391.7686.08613865389.48619752CS
43.383.8243946594388.3898.986.08755550491.45503585CS
1212.3315.523102102579.4398.977.74684396286.76318212CS
2626.4240.434649525665.3498.962.07694369278.24007566CS
5216.6522.167487684775.1198.962.07703940676.24536395CS
15621.7130.992148465470.0598.957.165716559173.11398241CS
26024.7937.016574585666.9798.956.56841815271.37498267CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PSTXPoseida Therapeutics Inc
$ 9.38
(227.97%)
30.14M
IMGCIMG Inc
$ 1.615
(156.35%)
114.51M
IDAIT Stamp Inc
$ 0.364
(102.22%)
560.18M
PGHLPrimega Group Holdings Ltd
$ 20.95
(98.77%)
2.89M
TOYOTOYO Company Ltd
$ 5.41
(86.55%)
49.09M
ALECAlector Inc
$ 2.575
(-34.97%)
8.13M
ABVEAbove Food Ingredients Inc
$ 0.5338
(-34.42%)
1.66M
LGCLLucas GC Ltd
$ 0.7511
(-33.53%)
2.48M
ADDColor Star Technology Company Ltd
$ 4.19
(-31.87%)
205.78k
LESLLeslies Inc
$ 2.445
(-30.34%)
24.55M
IDAIT Stamp Inc
$ 0.364
(102.22%)
560.18M
ELABElevai Labs Inc
$ 0.01255
(-21.07%)
325.82M
NVDANVIDIA Corporation
$ 136.92
(0.66%)
190.3M
RGTIRigetti Computing Inc
$ 2.195
(-20.18%)
126.72M
IMGCIMG Inc
$ 1.615
(156.35%)
114.51M

GILD Discussion

View Posts
fink fink 1 week ago
CEO is talking now.
The stock is selling off on great words.
Go figure! 6month Prep shot is a game changer. Generics are already being made for third world nations. These guys are going to eradicate AIDS.

They should be allowed to make a buck or two.
I want $250 a share please, I've held it way too long.
👍️0
Monksdream Monksdream 3 weeks ago
GILD, 10Q 11/6
👍️0
Monksdream Monksdream 1 month ago
GILD a new 52 week high
👍️0
Monksdream Monksdream 1 month ago
GILD new 52=week high
👍️0
jondoeuk jondoeuk 1 month ago
Two years later, and here are some of my takeaways...

- They know they need to expand into more (rural) areas and that might include pre-built clean rooms. Slides 21-26 show how difficult it is to drive uptake further. "Majority of future growth expected from establishing new ATC's in community." These centres need to establish new relationships with others for apheresis, local ER's for (CRS/ICANS) emergencies and even local freezer storage requirements, which is it's own thing. So much goes into treatment that has nothing to do with manufacturing.

- Forgot ZUMA-12 data was that good. A 86% CR rate and 81% three-year survival from 1L patients. Not sure how to compare that to later line trials, but decades from now, let's hope we are at the point we treat this front line (vs SOC now). Kite said their COGS is
👍️0
jondoeuk jondoeuk 1 month ago
''There have been more than 250 HIV vaccine trials, most of them early-stage, looking at whether the vaccine is safe and whether we mount an immune response following vaccination. There have been very few vaccine trials—10 or so—that have advanced to the point of looking at efficacy. Of those, one showed 31% efficacy at 42 months. That was the most promising trial, but the efficacy fell off very quickly, and it was only 31% and only against clade B. Whether that would translate to the other clades is not clear.'' https://publichealth.jhu.edu/2022/why-dont-we-have-an-hiv-vaccine
👍️0
jondoeuk jondoeuk 1 month ago
https://x.com/JackSha90859576/status/1847728103021281381
👍️0
TechandBio TechandBio 2 months ago
Wants to go higher!

$GILD
👍️0
Monksdream Monksdream 2 months ago
GILD approaching a 52 week high
👍️0
north40000 north40000 2 months ago
Featured on CNBC-TV this morning, 8:40 a.m. time frame.
👍️0
TechandBio TechandBio 4 months ago
NICE!

clutch stock with a disruptive cure prevention vaccine for HIV people would rather take 2 shots a year not to get HIV then taking oral pills for treatment!

$GILD
👍️0
TechandBio TechandBio 4 months ago
Adding shares and calls under $80..00

HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.



$GILD
$GILD
👍️0
midastouch017 midastouch017 4 months ago
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

FDA clearance triggers a $30 million milestone payment from Gilead
👍️0
Monksdream Monksdream 4 months ago
GILD under $100
👍️0
TechandBio TechandBio 4 months ago
Target is $100-$120 by Q2 2025

$GILD
👍️0
TechandBio TechandBio 4 months ago
HIV Prevention CURE Shot 2x a year

Great growing oncology pipeline!

my $80 vertical Calls from last week are looking golden!

$GILD
👍️0
north40000 north40000 5 months ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

"Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
👍️0
north40000 north40000 5 months ago
How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
👍️0
jondoeuk jondoeuk 6 months ago
There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
👍️0
jondoeuk jondoeuk 6 months ago
A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
👍️0
jondoeuk jondoeuk 6 months ago
They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
👍️0
jondoeuk jondoeuk 6 months ago
''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
👍️0
jondoeuk jondoeuk 6 months ago
The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
👍️0
jondoeuk jondoeuk 7 months ago
The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
👍️0
jondoeuk jondoeuk 8 months ago
IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
👍️0
jondoeuk jondoeuk 8 months ago
Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
👍️0
jondoeuk jondoeuk 8 months ago
Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
👍️0
jondoeuk jondoeuk 8 months ago
I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
👍️0
jondoeuk jondoeuk 8 months ago
Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
👍️0
Monksdream Monksdream 10 months ago
GILD new 52 week high
👍️0
jondoeuk jondoeuk 12 months ago
Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
👍️0
jondoeuk jondoeuk 1 year ago
Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them
👍️0
jondoeuk jondoeuk 1 year ago
The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
👍️0
Greedy G Greedy G 1 year ago
~bought 9/22 $80 calls .08c
👍️0
jondoeuk jondoeuk 2 years ago
Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
👍️0
DewDiligence DewDiligence 2 years ago
Why is an oral prodrug of Remdesivir anything to get excited about?
👍️0
jondoeuk jondoeuk 2 years ago
Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
👍️0
jondoeuk jondoeuk 2 years ago
Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
👍️0
fink fink 2 years ago
Christmas sell off over, last day to lock in any paper tax loss. LOL

Who’s losing money here?

I think we start the trend back up into Q1
👍️0
fink fink 2 years ago
It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.

That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
👍️0
PennyPusher786 PennyPusher786 2 years ago
It's at a 3 year high
👍️0
fung_derf fung_derf 2 years ago
Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

I_luv_cydy

Re: fung_derf post# 3875

Tuesday, May 19, 2020 2:32:23 PM

Post#
3878
of 4839
Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
👍️0
fink fink 2 years ago
Nice to see GILD over $80

Wonder if I should trim some? It’s been eating chit pie for some time.
Still don’t see why the spike.
👍️0
jondoeuk jondoeuk 2 years ago
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
👍️0
Zeppo Zeppo 2 years ago
Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
👍️0
DewDiligence DewDiligence 2 years ago
GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

The viewpoint in #msg-158260565 (from 2020) has not changed.
👍️0
mick mick 3 years ago
Gilead Sciences Inc (GILD)
59.77 ? -1.79 (-2.91%)
Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
Bid Ask Day's Range
59.53 60.0 59.27 - 62.06
GILD Detailed Quote
👍️0
jondoeuk jondoeuk 3 years ago
ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




👍️0
jondoeuk jondoeuk 3 years ago
Link to the audio recording https://investors.gilead.com/events/event-details/gilead-sciences-oncology-deep-dive
👍️0
jondoeuk jondoeuk 3 years ago
Oncology Deep Dive https://investors.gilead.com/static-files/332d0c81-fa18-44fa-82d3-babf96ca12d0

https://endpts.com/with-more-than-30-oncology-partners-gilead-lays-out-its-2030-vision-of-20-new-approvals/
👍️0

Your Recent History

NASDAQ
GILD
Gilead Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2158.56 only $755.50